DEVELOPMENT OF AN ALPHASCREEN-BASED HIGH-THROUGHPUT SCREENING ASSAY FOR INHIBITORS OF HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3

2011 ◽  
Vol 32 (3) ◽  
pp. 219-232 ◽  
Author(s):  
Ke Wang ◽  
Runlin Yang ◽  
Juan Xu ◽  
Yi Zhang ◽  
Lan Zhu ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
High Throughput ◽  
High Throughput Screening ◽  
Growth Factor Receptor ◽  
Vascular Endothelial ◽  
Screening Assay ◽  
High Throughput Screening Assay ◽  
Endothelial Growth Factor

scholarly journals Development of a chemiluminescent screening assay for detection of vascular endothelial growth factor receptor 1 ligands

2007 ◽  
Vol 366 (1) ◽  
pp. 108-110 ◽  
Author(s):  
Victor Goncalves ◽  
Benoit Gautier ◽  
Christiane Garbay ◽  
Michel Vidal ◽  
Nicolas Inguimbert
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Growth Factor Receptor ◽  
Vascular Endothelial ◽  
Screening Assay ◽  
Endothelial Growth Factor

Fortgeschrittenes medulläres Schilddrüsenkarzinom: Vandetanib verbessert das progressionsfreie Überleben

2012 ◽  
Vol 03 (02) ◽  
pp. 93-92
Author(s):  
Alexander Kretzschmar
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Phase Iii ◽  
Vascular Endothelial ◽  
Medulläres Schilddrüsenkarzinom ◽  
Epidermal Growth ◽  
Endothelial Growth Factor

Vandetanib ist ein oraler Hemmer des RET-Kinase-, VEGF (Vascular Endothelial Growth Factor Receptor)- und EGFR (Epidermal Growth Factor Receptor)-Signalwegs. In einer zulassungsrelevanten, randomisierten, doppelblinden, placebokontrollierten Phase- III-Studie verlängerte der Tyrosinkinasehemmer das progressionsfreie Überleben (PFS) signifikant länger als Placebo.

Sign in / Sign up

Export Citation Format

Share Document